What the FDA approval covers
On December 20, 2024, FDA approved Zepbound for treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity (BMI ≥30). This makes it the first GLP-1 (technically a GLP-1/GIP dual agonist) approved specifically for sleep apnea.
The approval rests on the SURMOUNT-OSA phase 3 trials — two parallel studies in 469 adults with moderate-severe OSA + obesity. Both included a CPAP-using cohort and a CPAP-naive cohort.
SURMOUNT-OSA trial results
Primary endpoint: change in apnea-hypopnea index (AHI) at 52 weeks. The result was substantial — Zepbound 15 mg group showed 51-52% reduction in AHI vs. 5-14% on placebo.
Roughly 25% of Zepbound participants achieved "complete resolution" of OSA (AHI <5) at 52 weeks, compared with ~5% on placebo. Mean weight loss was 18-20% — meaningful but not necessary for AHI reduction (the benefit appeared earlier than full weight loss).
Can Zepbound replace CPAP?
Not yet, per current sleep medicine guidance. The AASM 2025 position statement says Zepbound is additive to standard OSA care, not replacement. If you are on CPAP and tolerating it, continue.
Where it could replace CPAP: patients with mild-moderate OSA (AHI 15-30) who lose enough weight on Zepbound to drop below the OSA threshold (AHI <5). Re-titration of CPAP or weaning is appropriate at that point, under sleep specialist guidance.
Where CPAP stays: severe OSA (AHI >30), positional OSA that does not respond to weight loss, or central sleep apnea components.
Insurance coverage for Zepbound-as-OSA
Pre-approval (2023-2024), getting Zepbound covered for sleep apnea required BMI ≥30 + obesity diagnosis. Now: many plans will cover Zepbound with documented moderate-severe OSA at BMI ≥27 — sleep apnea is the comorbidity.
Your prescriber should submit: sleep study results (AHI), BMI, and any CPAP non-tolerance documentation. Medicare GLP-1 Bridge (July 1, 2026) includes Zepbound for OSA at $50/mo copay.
How to talk to your provider about it
If you have diagnosed OSA + obesity: ask your sleep specialist + PCP about adding Zepbound. Most sleep clinics in 2026 routinely discuss this option in follow-up visits.
If you suspect OSA but have not been studied: schedule a home sleep test or polysomnography first. AHI is the key number. Zepbound is approved only for moderate-severe OSA (AHI ≥15).
Frequently asked questions
- Is Zepbound FDA-approved for sleep apnea?
- Yes. FDA approved Zepbound for moderate-to-severe obstructive sleep apnea (AHI ≥15) in adults with obesity (BMI ≥30) on December 20, 2024.
- How much does Zepbound reduce AHI?
- In SURMOUNT-OSA, Zepbound 15 mg reduced AHI by 51-52% at 52 weeks vs. 5-14% on placebo. About 25% of participants achieved "complete resolution" (AHI <5).
- Can I stop CPAP if I start Zepbound?
- No — not without sleep specialist input. AASM 2025 guidance positions Zepbound as additive to CPAP, not replacement. Only after meaningful weight loss + repeat sleep study showing AHI <5 should weaning be considered.
- Does Mounjaro work for sleep apnea too?
- Same molecule (tirzepatide), same likely effect on AHI. But Mounjaro is FDA-approved for diabetes, not OSA — insurance coverage path differs. Zepbound is the OSA-approved branded version.
- Does Wegovy work for sleep apnea?
- Wegovy (semaglutide) is not FDA-approved for OSA. STEP-1 and follow-on trials show modest AHI reduction with semaglutide-driven weight loss, but the effect size is smaller than tirzepatide. Zepbound is the recommended choice for OSA + obesity.
Disclosure: Glpverdict is affiliate-funded but editorially independent. Some links above are sponsored — we may earn a commission if you sign up with a partner provider. This does not affect our editorial rankings or medical review.
